Clinical Trials Logo

Neuroectodermal Tumor clinical trials

View clinical trials related to Neuroectodermal Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01326104 Active, not recruiting - Medulloblastoma Clinical Trials

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor

Re-MATCH
Start date: September 7, 2010
Phase: Phase 2
Study type: Interventional

Immunotherapy is a specific approach to treating cancer that has shown promise in adult patients for the treatment of melanoma, malignant brain tumors, and other cancers. The study investigators will use the experience they have gained from these studies to try to improve the outcome for children affected by a recurrent brain tumor. Approximately 35 patients with first recurrence of medulloblastoma (reMB)/supratentorial primitive neuroectodermal tumors (PNETs) will be treated with tumor-specific immune cells and dendritic cell vaccines to see what impact they have on the tumor.